Cytokine Hemoadsorption in ECMO Patients

Cytokine Hemoadsorption in ECMO Patients

Sponsors

Lead Sponsor: University Medical Centre Ljubljana

Source University Medical Centre Ljubljana
Brief Summary

Cytokine hemoadsorption is a novel therapy used to improve outcome in critically ill patients with a dysregulated cytokine response and hemodynamic instability. Patients on extracorporeal membraneous oxygenation (ECMO) often develop severe systemic inflammatory response syndrome (SIRS). Cytokine removal using different types of hemoadsorption devices is believed to block the vicious circle of inflammation dysregulation when other basic therapeutic measures fail. To date there are very limited reports on ECMO and cytokine hemoadsorption combination therapy. The aim of this retrospective study is to evaluate feasibility and effectiveness of hemoadsorption in veno-arterial and veno-venous ECMO patients.

Overall Status Completed
Start Date 2017-06-01
Completion Date 2021-01-31
Primary Completion Date 2021-01-31
Study Type Observational
Primary Outcome
Measure Time Frame
Haemodynamic stabilization Within 12 hours after hemoadsorption
Secondary Outcome
Measure Time Frame
Lactate, interleukin-6, C-reactive protein and procalcitonin clearance Within 12 hours after hemoadsorption
Weaning from ECMO from day of ECMO-implant for every 24 hours until date of weaning or death, whichever came first, assessed up to 90 days
ICU length of stay from day of ICU-admission for every 24 hours until date of discharge or death, whichever came first, assessed up to 90 days
Hospital mortality from day of hospital admission until date of discharge or death, whichever came first, assessed up to 90 days
Enrollment 25
Condition
Eligibility

Sampling Method:

Non-Probability Sample

Criteria:

Inclusion Criteria: - VA/VV ECMO - hemoadsorption - Age ≥ 18 years Exclusion Criteria: - no additional exclusion criteria after being eligible for ECMO

Gender:

All

Minimum Age:

18 Years

Maximum Age:

N/A

Healthy Volunteers:

No

Location
Facility: University Medical Center Ljubljana
Location Countries

Slovenia

Verification Date

2021-05-01

Responsible Party

Type: Principal Investigator

Investigator Affiliation: University Medical Centre Ljubljana

Investigator Full Name: Jernej Berden

Investigator Title: Jernej Berden, MD, PhD

Keywords
Has Expanded Access No
Condition Browse
Arm Group

Label: Veno-arterial ECMO patients

Description: Patients with severe SIRS post extracorporeal cardiopulmonary resuscitation (ECPR) or accompanying cardiogenic shock who were treated with hemoadsorption.

Label: Veno-venous ECMO patients

Description: Patients with refractory septic shock on VV ECMO who were treated with hemoadsorption.

Study Design Info

Observational Model: Case-Only

Time Perspective: Retrospective

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News